News & Updates

Show Multimedia Only

Sacubitril/valsartan’s real-world benefits in HFrEF patients with ESRD

17 Jun 2025

In a real-world population of Korean patients with heart failure with reduced ejection fraction (HFrEF) and end-stage renal disease (ESRD) on haemodialysis, sacubitril/valsartan has demonstrated significant benefits vs renin-angiotensin system (RAS) blockade in reducing all-cause mortality and any hospitalization.

Sacubitril/valsartan’s real-world benefits in HFrEF patients with ESRD

17 Jun 2025

Sacubitril/valsartan reduces all-cause hospitalizations in HF

17 Jun 2025

In patients with chronic heart failure (HF) with below-normal left ventricular ejection fraction (LVEF), treatment with sacubitril/valsartan significantly reduces the risk of all-cause hospitalization vs renin-angiotensin system inhibitor (RASi), a post hoc pooled analysis of two pivotal trials has shown.

Sacubitril/valsartan reduces all-cause hospitalizations in HF

17 Jun 2025

Distinct comorbidity clusters in acute HF affect clinical outcomes

17 Jun 2025

A study involving 6,545 patients with acute heart failure (HF) has revealed five distinct groups of naturally clustered comorbidities, with the poorest postdischarge outcomes observed in the group with diabetes and chronic kidney disease (CKD), followed by the metabolic group and the elderly/atrial fibrillation (AF) group.

Distinct comorbidity clusters in acute HF affect clinical outcomes

17 Jun 2025

ARNI of benefit in HF patients with CKD

17 Jun 2025

Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has shown favourable cardiac and renal effects in patients with heart failure (HF) and chronic kidney disease (CKD) in a recent meta-analysis.

ARNI of benefit in HF patients with CKD

17 Jun 2025

SGLT2i extends survival in amyloidosis patients with or without HF

16 Jun 2025 by

Treatment with SGLT2 inhibitors can prolong the life of patients with amyloidosis with or without a diagnosis of heart failure (HF), a study has shown.

SGLT2i extends survival in amyloidosis patients with or without HF

16 Jun 2025

Phone-based strategy supports BP control after a stroke

13 Jun 2025 by

A nurse-led mobile health (mHealth) intervention that utilizes basic phones improves blood pressure (BP) control among stroke survivors in Ghana, as shown in the phase III PINGS-2 trial.

Phone-based strategy supports BP control after a stroke

13 Jun 2025

Wearables fare well for AF detection

13 Jun 2025 by

A systematic review and meta-analysis of 15 studies attest to the efficacy of single-lead electrocardiogram (ECG) smart chest patches and photoplethysmography (PPG)-based smartwatches for atrial fibrillation (AF) detection.

Wearables fare well for AF detection

13 Jun 2025

VTE event risk up in PD patients

12 Jun 2025 by

Researchers from Singapore found an elevated risk of venous thromboembolism (VTE) events in individuals with Parkinson’s disease (PD) in a systematic review and meta-analysis of 13 studies.

VTE event risk up in PD patients

12 Jun 2025

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

12 Jun 2025

At the Asia Vaccines and Antivirals Summit (AVAS) 2025 held in Bangkok, Thailand, two expert-led sessions provided valuable perspectives on the expanding role of oral antivirals in COVID-19 management. Dr Daniel Griffin, an infectious disease specialist and Clinical Instructor of Medicine at Columbia University, New York, US, focused on protecting high-risk populations through the timely use of antiviral therapy. Complementing this, Professor Ching-Tai Huang of Chang Gung University and Memorial Hospital in Taiwan offered practical guidance on clinical management strategies, including patient risk stratification and therapeutic selection.

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

12 Jun 2025

TRICH score predicts triple antihypertensive therapy need after ICH

10 Jun 2025 by

A team from the LKS Faculty of Medicine at the University of Hong Kong (HKU) has developed an innovative clinical tool to help physicians effectively identify intracerebral haemorrhage (ICH) patients who would benefit from early initiation of triple antihypertensive therapy to reduce the risks of ICH recurrence and subsequent strokes.

TRICH score predicts triple antihypertensive therapy need after ICH

10 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Sacubitril/valsartan’s real-world benefits in HFrEF patients with ESRD

Sacubitril/valsartan’s real-world benefits in HFrEF patients with ESRD

Sacubitril/valsartan reduces all-cause hospitalizations in HF

Sacubitril/valsartan reduces all-cause hospitalizations in HF

Distinct comorbidity clusters in acute HF affect clinical outcomes

Distinct comorbidity clusters in acute HF affect clinical outcomes

ARNI of benefit in HF patients with CKD

ARNI of benefit in HF patients with CKD

SGLT2i extends survival in amyloidosis patients with or without HF

SGLT2i extends survival in amyloidosis patients with or without HF

Phone-based strategy supports BP control after a stroke

Phone-based strategy supports BP control after a stroke

Wearables fare well for AF detection

Wearables fare well for AF detection

VTE event risk up in PD patients

VTE event risk up in PD patients

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

TRICH score predicts triple antihypertensive therapy need after ICH

TRICH score predicts triple antihypertensive therapy need after ICH